1. Home
  2. News
  3. Telix Pharmaceuticals Limited
  4. Telix Accelerates AI Development with Dedicaid Acquisition
More Telix Pharmaceuticals Limited news
Telix Pharmaceuticals LimitedASX: TLX

Telix Accelerates AI Development with Dedicaid Acquisition

Apr 26, 2023 at 6:32 PM EDT · Issued by Telix Pharmaceuticals Limited

Filed with ASX · Apr 26, 2023 at 6:32 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/telix-accelerates-ai-development-with-dedicaid-acquisition

Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20↗

Telix Pharmaceuticals Limited on 6ix

In the deck

  • Telix Pharmaceuticals — Corporate Update (April 2023)14 slidesApr 27, 2023

Earlier from Telix Pharmaceuticals

  • Q1 2023 Business update to accompany quarterly resultsApr 17, 2023
  • Appendix 4C and Activities Report - March 2023 QuarterApr 17, 2023
  • Telix Preclinical Development of Radiolabelled OlaratumabApr 16, 2023
  • Illuccix European Marketing Authorisation Application UpdateApr 2, 2023
  • FDA approval of expanded indication of Illuccix in the USMar 15, 2023

Later from Telix Pharmaceuticals

  • Presentation to Accompany AI Development Program UpdateApr 26, 2023
  • ZIRCON Data Presented at AUA Confirms Efficacy in 2cm MassesApr 30, 2023
  • Annual General Meeting - Chairman and CEO AddressesMay 23, 2023
  • Annual General Meeting - PresentationMay 24, 2023
  • Phase II study for indication expansion of TLX250-CDx dosesJun 18, 2023
All Telix Pharmaceuticals news releases↗

Follow Telix Pharmaceuticals into a list and get an email when it puts out news.

Follow Telix Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer